Literature DB >> 7589595

Hepatectomy for liver metastases from breast cancer.

D Elias1, P H Lasser, D Montrucolli, S Bonvallot, M Spielmann.   

Abstract

Thirty-two selected patients underwent laparotomy in an attempt to resect one or more isolated liver metastases (LM) from breast cancer. Only 21 of them had hepatectomy and systematic lymph node picking of the hepatic pedicle. In six patients (19%), the discovery of diffuse metastatic disease contraindicated hepatectomy and in five patients (16%), the diagnosis of LM was erroneous, for lesions proved to be benign liver tumours. Nineteen of the resected cases received preoperative chemotherapy, 12 received post-operative chemotherapy and two had repeated hepatectomy. Eight patients (38%) had more than one LM and (24%) had positive hepatic lymph nodes. No post-operative mortality occurred. After the beginning of this combined treatment, median survival was 38.2 months and 2- and 5-year survival rates were, respectively, 78% and 24%. After the hepatectomy, median survival was 26 months and 2- and 5-year survival rates were, respectively, 50% and 9%. When a recurrence did occur (mean time to recurrence after hepatectomy was 14.8 months) the liver was involved in 75% of the cases and was the first place of recurrence in 56% of the patients. In this limited series, the number of LM, the number of positive pedicular lymph nodes, and a response to preoperative chemotherapy were not significant prognostic factors. However, patients with negative nodes tended to have a better prognosis, as did those with the first and only site of relapse being the liver. These selected patients, treated with hepatectomy, had a median survival at least three-fold that of patients treated with standard, non-surgical treatment. However, hepatectomy appeared to be mainly a cytoreductive procedure, and the efficiency of this combined treatment was mainly hampered owing to the inefficacy of current chemotherapy programmes. Only a prospective randomized study, in well-defined patients with isolated LM from breast cancer, comparing conventional treatment with or without hepatectomy, will demonstrate whether hepatectomy does indeed increase survival rates.

Entities:  

Mesh:

Year:  1995        PMID: 7589595     DOI: 10.1016/s0748-7983(95)96972-1

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  15 in total

1.  Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.

Authors:  Daniel E Abbott; Antoine Brouquet; Elizabeth A Mittendorf; Andreas Andreou; Funda Meric-Bernstam; Vicente Valero; Marjorie C Green; Henry M Kuerer; Steven A Curley; Eddie K Abdalla; Kelly K Hunt; Jean-Nicolas Vauthey
Journal:  Surgery       Date:  2012-01-29       Impact factor: 3.982

2.  Treatment for liver metastases from breast cancer: results and prognostic factors.

Authors:  Xiao-Ping Li; Zhi-Qiang Meng; Wei-Jian Guo; Jie Li
Journal:  World J Gastroenterol       Date:  2005-06-28       Impact factor: 5.742

3.  Liver Resection for Non-colorectal Non-neuroendocrine Metastases: Where Do We Stand Today Compared to Colorectal Cancer?

Authors:  Tobias S Schiergens; Juliane Lüning; Bernhard W Renz; Michael Thomas; Sebastian Pratschke; Hao Feng; Serene M L Lee; Jutta Engel; Markus Rentsch; Markus Guba; Jens Werner; Wolfgang E Thasler
Journal:  J Gastrointest Surg       Date:  2016-02-26       Impact factor: 3.452

Review 4.  Improvement of survival and prospect of cure in patients with metastatic breast cancer.

Authors:  Yee Chung Cheng; Naoto T Ueno
Journal:  Breast Cancer       Date:  2011-05-13       Impact factor: 4.239

Review 5.  The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Shannon Banks; Nasreen Vohra; Zachary P Englert; Emmanuel E Zervos
Journal:  Langenbecks Arch Surg       Date:  2014-08-23       Impact factor: 3.445

6.  Surgical management of breast cancer liver metastases.

Authors:  Maria A Cassera; Chet W Hammill; Michael B Ujiki; Ronald F Wolf; Lee L Swanström; Paul D Hansen
Journal:  HPB (Oxford)       Date:  2011-04       Impact factor: 3.647

7.  Patient selection for surgical management of primary and metastatic liver cancers: current perspectives.

Authors:  J Alexander Palesty; Mazin Al-Kasspooles; John F Gibbs
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

8.  Radiofrequency ablation of metastatic lesions from breast cancer.

Authors:  C Bortolotto; S Macchi; L Veronese; R Dore; F Draghi; S Rossi
Journal:  J Ultrasound       Date:  2012-06-27

9.  Surgery for liver metastases from breast cancer.

Authors:  Dominique Elias; Daniela Di Pietroantonio
Journal:  HPB (Oxford)       Date:  2006       Impact factor: 3.647

10.  Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer.

Authors:  Thomas J Vogl; Nagy N N Naguib; Nour-Eldin A Nour-Eldin; Katrin Eichler; Stefan Zangos; Tatjana Gruber-Rouh
Journal:  Eur Radiol       Date:  2009-08-06       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.